Disease Domain | Count |
---|---|
Endocrinology and Metabolic Disease | 3 |
Nervous System Diseases | 2 |
Neoplasms | 2 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 5 |
Chemical drugs | 2 |
Herbal medicine | 2 |
Target- |
Mechanism- |
Active Org. |
Originator Org.- |
Inactive Indication |
Drug Highest PhaseNDA/BLA |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism SIRT3 agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 May 2025 |
Sponsor / Collaborator |
Start Date15 Apr 2025 |
Sponsor / Collaborator |
Start Date01 Apr 2025 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Qideng Mingmu Capsule | Macular Edema More | Phase 2 |
Hydroxysafflor Yellow A | Fibrosis, Liver More | Preclinical |
Forsythiaside A ( MAPK x NF-κB x PPAR x RXRs ) | Colitis More | Preclinical |
2-APQC ( SIRT3 ) | Cardiomegaly More | Preclinical |
Ginsenoside Rb1 ( DUSP1 x MFN2 x TMBIM6 x VDAC1 ) | Myocardial injury More | Preclinical |